Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14 Suppl 12
pubmed:dateCreated
2005-2-2
pubmed:abstractText
Primary systemic therapy (ie, preoperative or neoadjuvant) increases the possibility for breast-conserving surgery in patients with primary breast cancer. Patients with pathologic complete response to primary systemic therapy have improved survival compared with those with persistent tumors. Several phase II trials have evaluated gemcitabine-containing doublet or triplet regimens as primary systemic therapy for breast cancer, results of which have shown promising clinical and pathologic response rates with manageable toxicity. Results of a phase I/II study of gemcitabine (Gemzar)/epirubicin (Ellence)/docetaxel (Taxotere), or GEDoc, with prophylactic filgrastim (Neupogen), as primary systemic therapy in 77 evaluable patients with primary breast cancer are reported herein. Dose-limiting toxicities were grade 3 febrile neutropenia (n = 1) and grade 3 diarrhea (n = 2) at the fourth dose level of GEDoc tested (gemcitabine at 800 mg/m2 days 1 and 8, epirubicin at 90 mg/m2 day 1, and docetaxel at 75 mg/m2 day 1). As assessed by ultrasound, 92% of patients responded overall (22% complete response), and 79% of patients could undergo breast-conserving surgery. The pathologic complete response rate in resected breast tissue was 26%.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0890-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-31
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:15685823-Adult, pubmed-meshheading:15685823-Aged, pubmed-meshheading:15685823-Antimetabolites, Antineoplastic, pubmed-meshheading:15685823-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15685823-Breast Neoplasms, pubmed-meshheading:15685823-Chemotherapy, Adjuvant, pubmed-meshheading:15685823-Deoxycytidine, pubmed-meshheading:15685823-Dose-Response Relationship, Drug, pubmed-meshheading:15685823-Epirubicin, pubmed-meshheading:15685823-Female, pubmed-meshheading:15685823-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:15685823-Humans, pubmed-meshheading:15685823-Maximum Tolerated Dose, pubmed-meshheading:15685823-Middle Aged, pubmed-meshheading:15685823-Neoadjuvant Therapy, pubmed-meshheading:15685823-Recombinant Proteins, pubmed-meshheading:15685823-Taxoids, pubmed-meshheading:15685823-Time Factors, pubmed-meshheading:15685823-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Neoadjuvant therapy with gemcitabine in breast cancer.
pubmed:affiliation
University of Heidelberg, Department of Gynecology and Obstetrics, Heidelberg, Germany. andreas_schneeweiss@med.uni-heidelberg.de
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase I